Article

The Pittsburgh Lung Screening Study (PLuSS): outcomes within 3 years of a first computed tomography scan.

Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15232, USA.
American Journal of Respiratory and Critical Care Medicine (Impact Factor: 11.99). 11/2008; 178(9):956-61. DOI: 10.1164/rccm.200802-336OC
Source: PubMed

ABSTRACT The role of computed tomography (CT) screening for lung cancer is controversial, currently under study, and not yet fully elucidated.
To report findings from initial and 1-year repeat screening low-radiation-dose CT of the chest and 3-year outcomes for 50- to 79-year-old current and ex-smokers in the Pittsburgh Lung Screening Study (PLuSS).
Notified of findings on screening CT, subjects received diagnostic advice from both study and personal physicians. Tracking subjects for up to three years since initial screening, we obtained medical records to document diagnostic procedures, lung cancer diagnoses, and deaths.
3,642 and 3,423 subjects had initial and repeat screening. A total of 1,477 (40.6% of 3,624) were told about noncalcified lung nodules on the initial screening and, before repeat screening, 821 (55.6% of 1,477, 22.5% of 3,642) obtained one or more subsequent diagnostic imaging studies (CT, positron emission tomography [PET], or PET-CT). Tracking identified 80 subjects with lung cancer, including 53 subjects with tumor seen at initial screening. In all, 36 subjects (1.0% of the 3,642 screened), referred for abnormalities on either the initial or repeat screening, had a major thoracic surgical procedure (thoracotomy, video-assisted thoracoscopic surgery [VATS], median sternotomy, or mediastinoscopy) leading to a noncancer final diagnosis. Out of 82 subjects with thoracotomy or VATS to exclude malignancy in a lung nodule, 28 (34.1%) received a noncancer final diagnosis. Forty of 69 (58%) subjects with non-small cell lung cancer had stage I disease at diagnosis.
Though leading to the discovery of early stage lung cancer, CT screening also led to many diagnostic follow-up procedures, including major thoracic surgical procedures with noncancer outcomes.

Download full-text

Full-text

Available from: David O Wilson, Jul 17, 2015
0 Followers
 · 
165 Views
  • Source
    • "A recent survey of individuals with a high risk for developing lung cancer by the National Institutes of Health demonstrated that the patients screened through low-dose helical computed tomography (CT) had a 20% lower mortality rate than those screened by a traditional chest x-ray, presumably due to the improved image quality associated with the CT (Aberle et al. 2011). However, the relatively high cost of the helical CT, a limited access to this technology in some geographical areas, and problems of differentiating benign pulmonary nodules from lung cancer (Welch et al. 2007; Wilson et al. 2008), leading to higher-than-desired false-positive rates, have limited its widespread use. Molecular tests based on glycoconjugate measurements have also been developed to identify potential markers of lung cancer (Heo et al. 2007; Ueda et al. 2009; Zeng et al. 2010; Arnold et al. 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Glycosylation is a key post-translational protein modification which appears important in malignant transformation and tumor metastasis. Abnormal glycosylation of different proteins can often be measured in blood serum. In this study, we extend our serum-based structural investigations to samples provided by patients diagnosed with lung cancer, paying particular attention to the effects of smoking on the serum glycomic traces. Following a battery of glycomic tests, we find that several fucosylated tetra-antennary structures with varying degrees of sialylation are increased in their abundances in control samples provided by the former smokers, with further elevations in the lung cancer patients who were former smokers. Further detailed investigations demonstrated that the level of outer-arm fucosylation was elevated in the control samples of the former smokers and again in the lung cancer samples provided by the former smokers. This trend was particularly noticeable for the tri- and tetra-antennary structures. Different ratios of sialylation linkages were also observed that could be correlated with the different states-of-health and smoking status. Decreases in the abundance levels of isomers with two and three α2,3-linked sialic acids and an increased abundance of an isomer with two α2,6-linked sialic acids were noted for a fucosylated tri-sialylated tri-antennary glycan. These results demonstrate the long-term effects of smoking on glycomic profiles and that this factor needs to be considered in these and other serum-based analyses.
    Glycobiology 07/2012; DOI:10.1093/glycob/cws108 · 3.75 Impact Factor
  • Source
    • "Although cancer can be detected in an early stage by computed tomography (CT) screening (Henschke et al, 2006), results from randomised controlled trials are needed before deciding whether CT screening will reduce lung cancer mortality, and whether implementation of large-scale lung cancer CT screenings programmes should be recommended (Gohagan et al, 2004; Bach et al, 2007; van Iersel et al, 2007; Field and Duffy, 2008). Most CT screening studies report baseline rates of 14 – 43% of non-calcified nodules (5 – 10 mm in diameter); this relatively large range is attributed to geographic differences in nodule prevalence and the slice thickness used (Diederich et al, 2002; Wilson et al, 2008). Subjects with this type of nodule usually receive a recommendation to undergo a follow-up CT 3 – 4 months later to assess whether a nodule has grown, because nodule growth is associated with increased cancer risk (Swensen et al, 2005). "
    [Show abstract] [Hide abstract]
    ABSTRACT: In lung cancer CT screening, participants often have an indeterminate screening result at baseline requiring a follow-up CT. In subjects with either an indeterminate or a negative result after screening, we investigated whether health-related quality of life (HRQoL) changed over time and differed between groups in the short term. A total of 733 participants in the NELSON trial received four questionnaires: T0, before randomisation; T1, 1 week before the baseline screening; T2, 1 day after the screening; and T3, 2 months after the screening results but before the 3-month follow-up CT. HRQoL was measured as generic HRQoL (the 12-item Short Form, SF-12; the EuroQol questionnaire, EQ-5D), anxiety (the Spielberger State-Trait Anxiety Inventory, STAI-6), and lung-cancer-specific distress (the Impact of Event Scale, IES). For analyses, repeated-measures analysis of variance was used, adjusted for covariates. Response to each questionnaire was 88% or higher. Scores on SF-12, EQ-5D, and STAI-6 showed no clinically relevant changes over time. At T3, IES scores that were clinically relevant increased after an indeterminate result, whereas these scores showed a significant decrease after a negative result. At T3, differences in IES scores between the two baseline result groups were both significant and clinically relevant (P<0.01). This longitudinal study among participants of a lung cancer screening programme showed that in the short term recipients of an indeterminate result experienced increased lung-cancer-specific distress, whereas the HRQoL changes after a negative baseline screening result may be interpreted as a relief.
    British Journal of Cancer 11/2009; 102(1):27-34. DOI:10.1038/sj.bjc.6605459 · 4.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Computed tomography (CT) scanning has emerged as an effective means of early detection for lung cancer. Despite marked improvement over earlier methodologies, the low level of specificity demonstrated by CT scanning has limited its clinical implementation as a screening tool. A minimally-invasive biomarker-based test that could further characterize CT-positive patients based on risk of malignancy would greatly enhance its clinical efficacy. We performed an analysis of 81 serum proteins in 92 patients diagnosed with lung cancer and 172 CT-screened control individuals. We utilize a series of bioinformatics algorithms including Metropolis-Monte Carlo, artificial neural networks, Naïve Bayes, and additive logistic regression to identify multimarker panels capable of discriminating cases from controls with high levels of sensitivity and specificity in distinct training and independent validation sets. A three-biomarker panel comprised of MIF, prolactin, and thrombospondin identified using the Metropolis-Monte Carlo algorithm provided the best classification with a %Sensitivity/Specificity/Accuracy of 74/90/86 in the training set and 70/93/82 in the validation set. This panel was effective in the classification of control individuals demonstrating suspicious pulmonary nodules and stage I lung cancer patients. The selected serum biomarker panel demonstrated a high diagnostic utility in the current study and performance characteristics which compare favorably with previous reports. Further advancements may lead to the development of a diagnostic tool useful as an adjunct to CT-scanning.
    Cancer biomarkers: section A of Disease markers 01/2011; 10(1):3-12. DOI:10.3233/CBM-2012-0229 · 1.19 Impact Factor
Show more